Advertisement
Mayo Clinic Proceedings Home

Tricuspid Regurgitation Impact on Outcomes (TRIO): A Simple Clinical Risk Score

      Abstract

      Objective

      To determine which clinical variables infer the highest risk for mortality in patients with notable tricuspid regurgitation (TR) and to develop a clinical assessment tool (the Tricuspid Regurgitation Impact on Outcomes [TRIO] score).

      Patients and Methods

      A single-center retrospective cohort of 13,608 patients with undifferentiated moderate to severe TR at the time of index echocardiography between January 1, 2005, and December 31, 2016, was included. Baseline demographic and clinical data were obtained. Patients were randomly assigned to a training (N=10,205) and a validation (N=3403) cohort. Median follow-up was 6.5 years (interquartile range, 0.8 to 11.0 years). Variables associated with mortality were identified by Cox proportional hazards methods. A geographically distinct cohort of 7138 patients was used for further validation. The primary end point was all-cause mortality over 10 years.

      Results

      The 5-year probability of death was 53% for moderate TR, 63% for moderate-severe TR (hazard ratio [HR], 1.24 [95% CI, 1.17 to 1.31]; P<.001 vs moderate), and 71% for severe TR (HR, 1.55 [95% CI, 1.47 to 1.64]; P<.001 vs moderate). Factors associated with all-cause mortality on multivariate analysis included age 70 years or older, male sex, creatinine level greater than 2 mg/dL, congestive heart failure, chronic lung disease, aspartate aminotransferase level of 40 U/L or greater, heart rate of 90 beats/min or greater, and severe TR. Variables were assigned 1 or 2 points (HR, >1.5) and added to compute the TRIO score. The score was associated with all-cause mortality (C statistic = 0.67) and was able to separate patients into risk categories. Findings were similar in the second, independent and geographically distinct cohort.

      Conclusion

      The TRIO score is a simple clinical tool for risk assessment in patients with notable TR. Future prospective studies to validate its use are warranted.

      Abbreviations and Acronyms:

      AF (atrial fibrillation), AST (aspartate aminotransferase), CHF (congestive heart failure), HR (hazard ratio), LCL (lower control limit), TR (tricuspid regurgitation), TRIO (Tricuspid Regurgitation Impact on Outcomes), UCL (upper control limit)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Singh J.P.
        • Evans J.C.
        • Levy D.
        • et al.
        Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study) [published correction appears in Am J Cardiol. 1999;84(9):1143].
        Am J Cardiol. 1999; 83: 897-902
        • Stuge O.
        • Liddicoat J.
        Emerging opportunities for cardiac surgeons within structural heart disease [editorial].
        J Thorac Cardiovasc Surg. 2006; 132: 1258-1261
        • Topilsky Y.
        • Maltais S.
        • Medina Inojosa J.M.
        • et al.
        Burden of tricuspid regurgitation in patients diagnosed in the community setting.
        JACC Cardiovasc Imaging. 2019; 12: 433-442
        • Nath J.
        • Foster E.
        • Heidenreich P.A.
        Impact of tricuspid regurgitation on long-term survival.
        J Am Coll Cardiol. 2004; 43: 405-409
        • Topilsky Y.
        • Nkomo V.T.
        • Vatury O.
        • et al.
        Clinical outcome of isolated tricuspid regurgitation.
        JACC Cardiovasc Imaging. 2014; 7: 1185-1194
        • Fender E.A.
        • Petrescu I.
        • Ionescu F.
        • et al.
        Prognostic importance and predictors of survival in isolated tricuspid regurgitation: a growing problem.
        Mayo Clin Proc. 2019; 94: 2032-2039
        • Messika-Zeitoun D.
        • Thomson H.
        • Bellamy M.
        • et al.
        Medical and surgical outcome of tricuspid regurgitation caused by flail leaflets.
        J Thorac Cardiovasc Surg. 2004; 128: 296-302
        • Lee J.-W.
        • Song J.-M.
        • Park J.P.
        • Lee J.W.
        • Kang D.-H.
        • Song J.-K.
        Long-term prognosis of isolated significant tricuspid regurgitation.
        Circ J. 2010; 74: 375-380
        • Bar N.
        • Schwartz L.A.
        • Biner S.
        • et al.
        Clinical outcome of isolated tricuspid regurgitation in patients with preserved left ventricular ejection fraction and pulmonary hypertension.
        J Am Soc Echocardiogr. 2018; 31: 34-41
        • Benfari G.
        • Antoine C.
        • Miller W.L.
        • et al.
        Excess mortality associated with functional tricuspid regurgitation complicating heart failure with reduced ejection fraction.
        Circulation. 2019; 140: 196-206
        • Wang N.
        • Fulcher J.
        • Abeysuriya N.
        • et al.
        Tricuspid regurgitation is associated with increased mortality independent of pulmonary pressures and right heart failure: a systematic review and meta-analysis.
        Eur Heart J. 2019; 40: 476-484
        • Chorin E.
        • Rozenbaum Z.
        • Topilsky Y.
        • et al.
        Tricuspid regurgitation and long-term clinical outcomes.
        Eur Heart J Cardiovasc Imaging. 2020; 21: 157-165
        • Chen L.
        • Larsen C.M.
        • Le R.J.
        • et al.
        The prognostic significance of tricuspid valve regurgitation in pulmonary arterial hypertension.
        Clin Respir J. 2018; 12: 1572-1580
        • Padang R.
        • Chandrashekar N.
        • Indrabhinduwat M.
        • et al.
        Aetiology and outcomes of severe right ventricular dysfunction.
        Eur Heart J. 2020; 41: 1273-1282
        • Zack C.J.
        • Fender E.A.
        • Chandrashekar P.
        • et al.
        National trends and outcomes in isolated tricuspid valve surgery.
        J Am Coll Cardiol. 2017; 70: 2953-2960
        • Ingraham B.S.
        • Pislaru S.V.
        • Nkomo V.T.
        • et al.
        Characteristics and treatment strategies for severe tricuspid regurgitation.
        Heart. 2019; 105: 1244-1250
        • Kawsara A.
        • Alqahtani F.
        • Nkomo V.T.
        • et al.
        Determinants of morbidity and mortality associated with isolated tricuspid valve surgery.
        J Am Heart Assoc. 2021; 10e018417
        • Maeder M.T.
        • Holst D.P.
        • Kaye D.M.
        Tricuspid regurgitation contributes to renal dysfunction in patients with heart failure.
        J Card Fail. 2008; 14: 824-830
        • Agricola E.
        • Marini C.
        • Stella S.
        • et al.
        Effects of functional tricuspid regurgitation on renal function and long-term prognosis in patients with heart failure.
        J Cardiovasc Med (Hagerstown). 2017; 18: 60-68
        • Dietz M.F.
        • Prihadi E.A.
        • van der Bijl P.
        • Ajmone Marsan N.
        • Delgado V.
        • Bax J.J.
        Prognostic implications of staging right heart failure in patients with significant secondary tricuspid regurgitation.
        JACC Heart Fail. 2020; 8: 627-636
        • Dietz M.F.
        • Prihadi E.A.
        • van der Bijl P.
        • et al.
        Prognostic implications of right ventricular remodeling and function in patients with significant secondary tricuspid regurgitation.
        Circulation. 2019; 140: 836-845
        • Rana B.S.
        • Robinson S.
        • Francis R.
        • et al.
        Tricuspid regurgitation and the right ventricle in risk stratification and timing of intervention.
        Echo Res Pract. 2019; 6: R25-R39
        • Park J.-B.
        • Kim H.-K.
        • Jung J.-H.
        • et al.
        Prognostic value of cardiac MR imaging for preoperative assessment of patients with severe functional tricuspid regurgitation.
        Radiology. 2016; 280: 723-734
        • Kim S.M.
        • Singh H.S.
        • Nati J.
        • Ginns J.N.
        Multi-modality imaging in the evaluation and treatment of tricuspid regurgitation.
        Curr Treat Options Cardiovasc Med. 2018; 20: 77
        • Kilic A.
        • Saha-Chaudhuri P.
        • Rankin J.S.
        • Conte J.V.
        Trends and outcomes of tricuspid valve surgery in North America: an analysis of more than 50,000 patients from the Society of Thoracic Surgeons database.
        Ann Thorac Surg. 2013; 96: 1546-1552
        • Funkat A.-K.
        • Beckmann A.
        • Lewandowski J.
        • et al.
        Cardiac surgery in Germany during 2011: a report on behalf of the German Society for Thoracic and Cardiovascular Surgery.
        Thorac Cardiovasc Surg. 2012; 60: 371-382
        • Kelly B.J.
        • Ho Luxford J.M.
        • Butler C.G.
        • et al.
        Severity of tricuspid regurgitation is associated with long-term mortality.
        J Thorac Cardiovasc Surg. 2018; 155: 1032-1038.e2
        • Karam N.
        • Braun D.
        • Mehr M.
        • et al.
        Impact of transcatheter tricuspid valve repair for severe tricuspid regurgitation on kidney and liver function.
        JACC Cardiovasc Interv. 2019; 12: 1413-1420

      Linked Article

      • TRIO Risk Score: Simple, Yet Complex
        Mayo Clinic ProceedingsVol. 97Issue 8
        • Preview
          Tricuspid regurgitation (TR) occurs in 65% to 85% of the population in the United States.1,2 Although mild TR in the setting of a structurally normal tricuspid valve apparatus can be considered a normal variant, progression to moderate-severe TR increases with age and is estimated to affect nearly 1.6 million adults in the United States.3 Echocardiographic data from the Framingham Heart Study reported an overall prevalence of moderate or higher TR of 0.8%, with a majority due to functional TR and only 10% due to an organic cause.
        • Full-Text
        • PDF